US Measles Cases Reach Decade High as Vaccination Rates Drop

The United States has reported its highest number of measles cases in decades, with 1,400 confirmed infections in 2025, according to the Centers for Disease Control and Prevention. The surge follows a decline in vaccination coverage, which fell to 74 % for the measles‑mumps‑rubella (MMR) vaccine last year, below the 95 % threshold needed for herd immunity. Health officials attribute the uptick to vaccine hesitancy, disruptions in routine immunization services during the COVID‑19 pandemic, and the spread of misinformation on social media.

In response, a coalition of academic and pharmaceutical researchers is accelerating the development of therapeutic options for those who contract measles or are at high risk of severe disease. Early-stage trials are evaluating monoclonal antibodies that target the measles virus envelope protein, while other studies are exploring antiviral compounds that inhibit viral replication. The goal is to provide a short‑course treatment that could reduce complications such as pneumonia, encephalitis, and post‑infectious immune disorders, especially in infants, pregnant women, and immunocompromised patients.

If successful, these drugs could complement existing public health measures by offering a medical countermeasure for measles outbreaks and protecting vulnerable populations. Meanwhile, public health agencies are urging parents to keep children up‑to‑date with the MMR vaccine and to seek prompt medical care if symptoms such as fever, rash, or cough appear. The dual strategy of strengthening vaccination coverage and developing targeted therapies aims to curb the current resurgence and prevent future spikes in measles cases.